Clene Inc.
CLNN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLNN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLNN
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing its lead drug candidate, CNM-Au8, for neurodegenerative diseases, currently facing substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for Clene Inc..
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing its lead drug candidate, CNM-Au8, for neurodegenerative diseases, currently facing substantial doubt about its ability to continue as a going concern.
- Lead drug candidate is CNM-Au8, with substantially all R&D expenses directed toward it [sec_mda · as of 2026-08-14].
- Cash and cash equivalents totaled $9.7 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Accumulated deficit was $329.8 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net cash used in operating activities was $7.1 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-14].
- The company has expressed substantial doubt about its ability to continue as a going concern beyond one year [sec_mda · as of 2026-08-14].
What works
- Clene has advanced CNM-Au8 through clinical development and is preparing to file a New Drug Application (NDA) with the FDA [sec · filed 2026-05-05].
- The company received indirect financial support from the HEALEY ALS Platform Trial, which conducted an ALS platform trial of CNM-Au8 at significantly lower costs than a comparable trial [sec_mda · as of 2026-05-14].
- Clene has implemented cost-saving initiatives, including delaying certain R&D programs and reducing employee compensation [sec_mda · as of 2026-05-14].
What to weigh
- Clene has incurred significant losses and negative cash flows since inception, with no significant revenue generated [sec_mda · as of 2026-08-14].
- The company has concluded that its plans do not alleviate substantial doubt about its ability to continue as a going concern beyond one year [sec_mda · as of 2026-05-14].
- Cash and cash equivalents were only $9.7 million as of June 30, 2026, against an accumulated deficit of $329.8 million [sec_mda · as of 2026-08-14].
- The company faces uncertainty in securing additional financing on favorable terms, if at all [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Clene has substantial doubt about its ability to continue as a going concern.
“we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.”
SEC MD&A · May 14, 2026
Clene's lead drug candidate is CNM-Au8.
“substantially all our research and development expenses relating to our lead asset, CNM-Au8.”
SEC MD&A · August 14, 2026
Clene's cash position as of June 30, 2026.
“Our cash and cash equivalents totaled $9.7 million and $5.2 million as of June 30, 2026 and December 31, 2025, respectively”
SEC MD&A · August 14, 2026
Clene's accumulated deficit as of June 30, 2026.
“Our accumulated deficit was $329.8 million and $308.3 million as of June 30, 2026 and December 31, 2025, respectively.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern beyond one year [sec_mda · as of 2026-05-14].
- Limited cash runway — Only $9.7M cash as of June 30, 2026, with high cash burn rate [sec_mda · as of 2026-08-14].
- No revenue from operations — No significant revenue generated since inception; depends on regulatory approval [sec_mda · as of 2026-08-14].
- Financing risk — No assurance of securing additional equity or debt financing on favorable terms [sec_mda · as of 2026-08-14].
What to watch
- Ability to secure additional financing to fund operations and NDA filing for CNM-Au8 [sec_mda · as of 2026-08-14].
- Progress of the NDA preparation and filing for CNM-Au8 [sec · filed 2026-05-05].
- Outcome of cost-saving initiatives and their impact on cash runway [sec_mda · as of 2026-05-14].
- Any updates on the HEALEY ALS Platform Trial results or regulatory interactions [sec_mda · as of 2026-05-14].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Clene Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Clene Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.1 months
OCF -$3M · Net income -$13M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 20 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$6.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 616,460 | $3.0M |
| scoggin management lp | 300,000 | $1.5M |
| geode capital management, llc | 95,874 | $473K |
| peak6 llc | 50,012 | $247K |
| vanguard fiduciary trust co | 43,715 | $216K |
| parsons capital management inc/ri | 37,243 | $184K |
| blackrock, inc. | 33,799 | $167K |
| state street corp | 29,801 | $147K |
| morgan stanley | 19,832 | $98K |
| northern trust corp | 16,143 | $80K |
Showing top 10 of 25 institutional holders of Clene Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 10.2%
- Days to cover
- 10.4
- Shares short
- 875,026
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLNN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Clene Inc.?
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing its lead drug candidate, CNM-Au8, for neurodegenerative diseases, currently facing substantial doubt about its ability to continue as a going concern.
What is Clene Inc.'s lead drug candidate?
Clene Inc.'s most advanced tracked candidate is cnm-au8 (Phase 2) for Multiple Sclerosis; Amyotrophic Lateral Sclerosis; ALS.
Who is the CEO of Clene Inc.?
Mr. Robert Etherington MBA is the chief executive officer of Clene Inc. (CLNN).
Where is Clene Inc. headquartered?
Clene Inc. (CLNN) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does Clene Inc. focus on?
Clene Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.